ClinicalTrials.gg
TerminatedNCT03343613Updated Jun 9, 2020

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

A Phase 1 interventional study of LY3381916 and LY3300054 in Solid Tumor, Non Small Cell Lung Cancer and Renal Cell Carcinoma, sponsored by Eli Lilly and Company. Terminated at 12 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-09.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Why this study was terminated
Study terminated due to strategic business decision by Eli Lilly and Company.

From the registry’s dates

  • Primary completion was Feb 2020, 6 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.

Enrollment
98th of 139
60 · median 109
Started
2017
with 1 other
Phase 1
28 of 147
3 open now
Registered
122nd of 147
by date

Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 98th largest by enrollment of the 139 interventional ones that give a count, is one of 2 that started in 2017, is one of 28 in phase 1, and was the 122nd registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).

03

Conditions studied

  • Solid Tumor
  • Non Small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Triple Negative Breast Cancer

Keywords

  • IDO-1 Inhibitor
  • IDO1 Inhibitor
  • IDO Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dose escalation phase: Participant must have histological or cytological evidence of a diagnosis of cancer that is advanced and/or .
  • Dose expansion B1: Metastatic TNBC participants who have not received prior /L1 treatment.
  • Dose expansion B2: Metastatic NSCLC participants who have progressed on prior PD-L1/L1 treatment.
  • Dose expansion B3: Metastatic clear cell carcinoma RCC who have progressed on prior PD-L1/L1 treatment.
  • Have adequate organ function.
  • Have a performance status (PS) of ≤1 on the (ECOG) scale.
  • Are able and willing to provide required, newly acquired tumor .
  • Have discontinued previous treatments for cancer.
  • Are able to swallow capsules.

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in a clinical study.
  • Have known symptomatic central nervous system or carcinomatous meningitis.
  • Have a serious concomitant systemic disorder.
  • Have a symptomatic infection or symptomatic activated/reactivated or C.
  • Have a significant cardiac condition.
  • Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor.
  • Have an active disease or currently require of >10 milligrams of prednisone or equivalent per day.
  • Have interstitial lung disease or (noninfectious) pneumonitis, participants with a history of (noninfectious) pneumonitis that required to assist with management.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    LY3381916 Escalation

    LY3381916 administered orally.

    Drug: LY3381916

  • Experimental
    LY3381916 + LY3300054 Escalation

    LY3381916 administered orally and LY3300054 administered intravenously (IV).

    Drug: LY3381916 · Drug: LY3300054

  • Experimental
    LY3381916 Expansion

    LY3381916 administered orally.

    Drug: LY3381916

  • Experimental
    LY3381916 + LY3300054 Expansion B1

    Metastatic triple negative breast cancer (TNBC) LY3381916 administered orally and LY3300054 administered IV.

    Drug: LY3381916 · Drug: LY3300054

  • Experimental
    LY3381916 + LY3300054 Expansion B2

    Metastatic non-small cell lung cancer (NSCLC) LY3381916 administered orally and LY3300054 administered IV.

    Drug: LY3381916 · Drug: LY3300054

  • Experimental
    LY3381916 + LY3300054 Expansion B3

    Metastatic clear cell carcinoma renal cell carcinoma (RCC) LY3381916 administered orally and LY3300054 administered IV.

    Drug: LY3381916 · Drug: LY3300054

Interventions

  • DrugLY3381916

    IDO-1 inhibitor administered orally

  • PD-L1 inhibitor administered IV

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLTs)

    Number of participants with DLTs

    Time frame: Baseline through Cycle 1 (28 Day Cycle)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3381916

    PK: Cmax of LY3381916

    Time frame: Predose Lead in Day 1 through Cycle 3 Day 1

  2. PK: Area Under the Plasma Concentration Curve (AUC) of LY3381916

    PK: AUC of LY3381916

    Time frame: Predose Lead in Day 1 through Cycle 3 Day 1

  3. PK: Cmax of LY3381916 Administered in Combination with LY3300054

    PK: Cmax of LY3381916 administered in combination with LY3300054

    Time frame: Predose Cycle 1 Day 1 through Cycle 3 Day 1

  4. PK: AUC of LY3381916 Administered in Combination with LY3300054

    PK: AUC of LY3381916 administered in combination with LY3300054

    Time frame: Predose Cycle 1 Day 1 through Cycle 3 Day 1

  5. PK: Cmax of LY3300054 Administered in Combination with LY3381916

    PK: Cmax of LY3300054 administered in combination with LY3381916

    Time frame: Predose Cycle 1 Day 1 through Cycle 3 Day 1

  6. PK: Minimum Plasma Concentration (Cmin) of LY3300054 Administered in Combination with LY3381916

    PK: Cmin of LY3300054 administered in combination with LY3381916

    Time frame: Predose Cycle 1 Day 1 through Cycle 3 Day 1

  7. Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR)

    ORR: Percentage of participants with a CR or PR

    Time frame: Baseline through Measured Progressive Disease (Estimated up to 12 Months)

  8. Time to Response (TTR)

    TTR

    Time frame: Baseline to Date of CR or PR (Estimated up to 12 Months)

  9. Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR

    DCR: Percentage of participants who exhibit SD, CR or PR

    Time frame: Baseline through Measured Progressive Disease (Estimated up to 12 Months)

  10. Duration of Response (DOR)

    DOR

    Time frame: Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)

  11. Progression Free Survival (PFS)

    PFS

    Time frame: Baseline to Objective Progression or Death Due to Any Cause (Estimated Up to 12 Months)

07

Study locations

12 sites
  • IU Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Sarah Cannon Research Institute SCRI
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • Institut Jules Bordet
    Brussel, 1000, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Finsen Institute
    Copenhagen, 2100, Denmark
  • Gustave Roussy
    Villejuif Cedex, 94805, France
  • Azienda Ospedaliera San Gerardo
    Monza, Milano 20052, Italy
  • Azienda Ospedaliera Umberto I
    Ancona, 60100, Italy
  • Hospital Clinico Universitario Virgen de la Victoria
    Malaga, Andalucia 29010, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Feb 2020, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2017
First posted
Nov 17, 2017
StartActual
Nov 17, 2017
Primary completionActual
Feb 7, 2020
CompletionActual
May 4, 2020
Last update
Jun 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03343613
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 17, 2017
Primary completion
Feb 7, 2020
Completion
May 4, 2020
Last update
Jun 9, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion